A human papillomavirus (HPV)-related malignancy, preventable by HPV vaccination, screening, and treatment of high-grade dysplasia.
Cervical cancer screening by cervical cytology (Pap testing) may detect pre-invasive disease. HPV testing can also be used for screening, but is not recommended in women under the age of 30 years.
Locally advanced disease may present with bleeding, discharge, pain, or obstructive uropathy.
Staging using International Federation of Gynecology and Obstetrics criteria is based on clinical assessment only. When available, advanced imaging modalities (MRI, PET, PET/CT, CT) are used to evaluate the local extent of disease and to screen for metastases, which may guide treatment planning.
For microinvasive disease, treatment with conisation is recommended.
For early stage invasive disease, surgery is recommended.
For locally advanced disease, chemoradiotherapy is significantly superior to radiotherapy alone.
Cervical cancer is a human papillomavirus-related malignancy of the uterine cervical mucosa.
Medical Gynecologic Oncology
Division of Hematology Oncology
Massachusetts General Hospital
RTP is a paid participant in scientific advisory boards for Genentech/Roche. RTP is an author of a number of references cited in this topic.
Department of Radiation Oncology
Brigham and Women’s Hospital
LJL declares that she has no competing interests.
Dr Richard T. Penson and Dr Larissa J. Lee would like to gratefully acknowledge Dr Neil S. Horowitz and Dr Anthony H. Russell, previous contributors to this topic. NSH and AHR declare that they have no competing interests.
Minimally Invasive Gynecologic Surgery
Magee Women's Hospital
University of Pittsburgh Medical Center
LY declares that she has no competing interests.
Consultant in Obstetrics & Gynaecology
Lead Clinician in Colposcopy
Imperial College Healthcare NHS Trust
DL declares that she has no competing interests.
Use of this content is subject to our disclaimer